[
  {
    "ts": null,
    "headline": "Wall Street Brunch: Tesla Shareholders Set To Vote On Musk's Pay",
    "summary": "Listen below or on the go via Apple Podcasts and SpotifyThe following is an abridged transcript:Tesla (TSLA) will hold its highly-anticipated shareholder...",
    "url": "https://finnhub.io/api/news?id=4f368e74b1c30393a9390a67f57bb6e3f80ffe0e687597d8a287abf0d88f706f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762091957,
      "headline": "Wall Street Brunch: Tesla Shareholders Set To Vote On Musk's Pay",
      "id": 137296438,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156387592/image_2156387592.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Listen below or on the go via Apple Podcasts and SpotifyThe following is an abridged transcript:Tesla (TSLA) will hold its highly-anticipated shareholder...",
      "url": "https://finnhub.io/api/news?id=4f368e74b1c30393a9390a67f57bb6e3f80ffe0e687597d8a287abf0d88f706f"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Royalty Pharma (RPRX) Could Change Following $2 Billion Debt Raise and New Royalty Deals",
    "summary": "Recently, Royalty Pharma raised US$2 billion through senior unsecured notes and acquired royalty interests in Amgen's cancer drug IMDELLTRA, while also committing up to US$300 million for a royalty on Zenas BioPharma’s autoimmune drug candidate tied to clinical milestones. These moves reflect Royalty Pharma's focus on building a diversified, lower-risk revenue portfolio by investing in high-value, late-stage, and marketed drug assets. We'll explore how Royalty Pharma’s sizable funding...",
    "url": "https://finnhub.io/api/news?id=dbe32f36c794d224b694902603bfecba0785062f2adf14e7f0622107106ac570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762089149,
      "headline": "The Bull Case For Royalty Pharma (RPRX) Could Change Following $2 Billion Debt Raise and New Royalty Deals",
      "id": 137294787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Recently, Royalty Pharma raised US$2 billion through senior unsecured notes and acquired royalty interests in Amgen's cancer drug IMDELLTRA, while also committing up to US$300 million for a royalty on Zenas BioPharma’s autoimmune drug candidate tied to clinical milestones. These moves reflect Royalty Pharma's focus on building a diversified, lower-risk revenue portfolio by investing in high-value, late-stage, and marketed drug assets. We'll explore how Royalty Pharma’s sizable funding...",
      "url": "https://finnhub.io/api/news?id=dbe32f36c794d224b694902603bfecba0785062f2adf14e7f0622107106ac570"
    }
  },
  {
    "ts": null,
    "headline": "Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week",
    "summary": "Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.",
    "url": "https://finnhub.io/api/news?id=a90459f9d470a052272eeacfe0a45722c71f3c3a1ec2c0c4fbb19b824e28cb8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762087573,
      "headline": "Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week",
      "id": 137294329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.",
      "url": "https://finnhub.io/api/news?id=a90459f9d470a052272eeacfe0a45722c71f3c3a1ec2c0c4fbb19b824e28cb8a"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Week Ahead",
    "summary": "Get the latest stock market updates, key earnings previews, and gold investing insights.",
    "url": "https://finnhub.io/api/news?id=8834350af1a837126d8db68e94fded0a34364f99b03586b0dad5dee085578cc3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762067228,
      "headline": "Wall Street Week Ahead",
      "id": 137292957,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451753827/image_1451753827.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Get the latest stock market updates, key earnings previews, and gold investing insights.",
      "url": "https://finnhub.io/api/news?id=8834350af1a837126d8db68e94fded0a34364f99b03586b0dad5dee085578cc3"
    }
  },
  {
    "ts": null,
    "headline": "A Fresh Look at Amgen (AMGN) Valuation After Key EU Drug Approval and Upcoming Clinical Data Releases",
    "summary": "Amgen (AMGN) received a key approval from the European Commission for Tezspire as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, following strong Phase III results. The company is also preparing to share late-stage Repatha clinical data at an upcoming cardiology meeting, and its third quarter earnings report is just around the corner. See our latest analysis for Amgen. Amgen’s share price has climbed 15.1% year-to-date, supported by pipeline progress and steady product...",
    "url": "https://finnhub.io/api/news?id=d780bbc04e858c4b59496e877a1abe0b47969190a4d73dfa895ddbcf697f42fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762060280,
      "headline": "A Fresh Look at Amgen (AMGN) Valuation After Key EU Drug Approval and Upcoming Clinical Data Releases",
      "id": 137294789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) received a key approval from the European Commission for Tezspire as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, following strong Phase III results. The company is also preparing to share late-stage Repatha clinical data at an upcoming cardiology meeting, and its third quarter earnings report is just around the corner. See our latest analysis for Amgen. Amgen’s share price has climbed 15.1% year-to-date, supported by pipeline progress and steady product...",
      "url": "https://finnhub.io/api/news?id=d780bbc04e858c4b59496e877a1abe0b47969190a4d73dfa895ddbcf697f42fb"
    }
  }
]